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Background: Lysophosphatidic acid (LPA) is a bioactive lipid with pleiotropic activities due to activation of six receptors
(LPA1–6).
Results: Genetic deletion and pharmacological blockade of LPA1 inhibit differentiation and bone degradation activity of
osteoclasts.
Conclusion: LPA controls bone homeostasis through the activation of LPA1 expressed by osteoclasts.
Significance: LPA1 is a new therapeutic target of diseases with excess bone degradation.
Lysophosphatidic acid (LPA) is a natural bioactive lipid that
acts through six differentG protein-coupled receptors (LPA1–6)
with pleiotropic activities onmultiple cell types.We have previ-
ously demonstrated that LPA is necessary for successful in vitro
osteoclastogenesis of bone marrow cells. Bone cells controlling
bone remodeling (i.e. osteoblasts, osteoclasts, and osteocytes)
express LPA1, but delineating the role of this receptor in bone
remodeling is still pending. Despite Lpar1/mice displaying a
low bone mass phenotype, we demonstrated that bone marrow
cell-induced osteoclastogenesis was reduced in Lpar1/ mice
but not in Lpar2/ and Lpar3/ animals. Expression of LPA1
was up-regulated during osteoclastogenesis, and LPA1 antago-
nists (Ki16425, Debio0719, andVPC12249) inhibited osteoclast
differentiation. Blocking LPA1 activity with Ki16425 inhibited
expression of nuclear factor of activated T-cell cytoplasmic 1
(NFATc1) and dendritic cell-specific transmembrane protein
and interfered with the fusion but not the proliferation of
osteoclast precursors. Similar to wild type osteoclasts treated
with Ki16425, mature Lpar1/ osteoclasts had reduced podo-
some belt and sealing zone resulting in reduced mineralized
matrix resorption. Additionally, LPA1 expression markedly
increased in the bone of ovariectomized mice, which was
blocked by bisphosphonate treatment. Conversely, systemic
treatment with Debio0719 prevented ovariectomy-induced
cancellous bone loss. Moreover, intravital multiphoton micros-
copy revealed that Debio0719 reduced the retention of
CX3CR1-EGFP osteoclast precursors in bone by increasing
their mobility in the bone marrow cavity. Overall, our results
demonstrate that LPA1 is essential for in vitro and in vivo oste-
oclast activities. Therefore, LPA1 emerges as a new target for the
treatment of diseases associated with excess bone loss.
Bone diseases associated with excessive bone loss are among
themost prevalent disorders in the population. Hormonal dep-
rivation, inflammation, bone metastasis, and many of the can-
cer therapeutics alter bone structure, resulting in bone fragility
and increased risk of fracture (1). Bone is a complex tissue in
which integrity is maintained over the lifetime by the continu-
ous process of bone remodeling supported by specialized bone
cells as follows: osteoclasts that resorb bone and osteoblasts
that form new bone. Signals emerging from osteocytes (2),
immune cells (3), the nervous system (4), as well as hormonal
regulation (5) control bone remodeling and modulate cross-
talk between osteoclasts and osteoblasts.
Lysophosphatidic acid (LPA)5 is a natural bioactive phospho-
lipid, exhibiting growth factor-like activities on a range of dif-
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ferent cell types, including bone cells (6–9). These activities
involve the induction of cytoskeletal rearrangement, cell motil-
ity, survival, proliferation, and differentiation (10). Blood plate-
lets are the major source of LPA (11), but we have previously
shown that LPA is produced at bone sites in the context of bone
metastasis, acting on cancer cells and osteoclasts to promote
progression of osteolytic lesions and bone loss (12). More
recently, osteoblasts were shown to produce LPA through
the involvement of purinergic P2X7 receptor, suggesting that
these cells might be an additional source of LPA in bone (13).
However, the role of LPA and its cognate receptors in vivo on
bone cells and bone turnover is not well understood.
The effects of LPA are mediated by at least six different G
protein-coupled receptors (LPA1–6) (14, 15). These receptors
share intracellular signaling pathways dependent on Gi
(LPA1–4 andLPA6),G12/13 (LPA1–2 andLPA4–6),Gq (LPA1–5),
and GS (LPA4 and LPA6) (16, 17). Therefore, LPA receptors
can have potentially redundant or opposite effects on cell biol-
ogy.Most eukaryotic cells, including bone cells, express numer-
ous LPA receptors. Consequently, pleiotropic activities of LPA
are likely dependent on co-activation signals mediated by mul-
tiple receptors. As a consequence, activation of different cell
types in bone may underlie the complex mode of action of LPA
in bone pathophysiology (18).
Lpar1/mice have revealed a rich biology and pathophys-
iology, affecting the brain (19–23) as well as other organ sys-
tems like the lung (24), the intestine (25), cardiovascular system
(26), the adipose tissue (27), and bone (28). Lpar2/ mice do
not exhibit an obvious phenotype (29). In contrast, Lpar3/
female mice are sterile due to defects in embryo implantation
(30), and Lpar3/ male mice have age-dependent loss of
spermproduction (31), indicating a prevalent role of this recep-
tor in the genital tract. Lpar4/ animals showed vascular
defects during embryonic development (32) and an osteope-
trotic bone phenotype (33). Lpar5/ mice showed reduced
susceptibility to pain (34).
LPA plays a key role during bone development as revealed by
a low bonemass phenotype of Lpar1/mice associated with a
low osteoblastic activity and growth retardation due to inhibi-
tion of chondrocyte proliferation, defects in endochondral ossi-
fication (28), and increased bone formation in Lpar4/ ani-
mals (33). These reports suggest that LPA1 and LPA4 might
have opposite functions in osteoblasts during bone develop-
ment. In addition to adipogenesis and glucose tolerance defects
(27), Lpar1/ mice present developmental abnormalities in
the olfactory bulb that markedly impaired pup suckling behav-
ior (19). Deficiencies of the cerebral cortex, food intake, and
metabolic regulations are prone to compromise bone homeo-
stasis indirectly. In addition, LPA1 is the most ubiquitous LPA
receptor in mammalian tissues (35), expressed in both osteo-
blasts and osteoclasts (8, 28). Therefore, the bone phenotype of
Lpar1/ mice is likely to be a consequence of multiple con-
straints of bone remodeling involving disruption of both osteo-
blast and osteoclast activity. Here, we provide the first demon-
stration that LPA1 controls in vitro osteoclast differentiation
regulating nuclear factor of activated T-cells cytoplasmic 1
(NFATc1) and dendritic cell-specific transmembrane protein
(DC-STAMP) expressions, bone resorption establishing func-
tionally active sealing zone, and in vivo controlling motility of
osteoclast progenitors in the bone marrow cavity and osteo-
clast-mediated bone loss induced by ovariectomy.
EXPERIMENTAL PROCEDURES
Drugs and Reagents—Three competitive inhibitors of LPA
signaling pathways dependent on LPA1 and LPA3 receptors
VPC12249 (Coger, Morillon, France), Ki16425 (Interchim,
Montluçon, France), and Debio0719 (generous gift of Dr.
Murone, Debiopharm Group, Lausanne, Switzerland) were
used (36–38). No antagonist activity of Ki16425 was detected
on LPA4, LPA5, and LPA6 (37, 39, 40). No data are currently
available supporting antagonist activities of Debio0719 and
VPC12249 on these receptors. Zoledronic acid was obtained
from Novartis (Basel, Switzerland). Risedronate was obtained
from Procter & Gamble Pharmaceuticals (Cincinnati, OH).
Animal Studies—Mice used at the Université Claude Ber-
nard Lyon1 (Lyon, France) were handled according to the rules
of Décret Number 87-848 of October 19, 1987, Paris. The
experimental protocol have been reviewed and approved by the
Institutional AnimalCare andUseCommittee of theUniversité
Claude Bernard Lyon-1 (Lyon, France). Animal experiments
performed at the University of Sheffield were carried out in
accordancewith local guidelines andwith home office approval
under Project License 40/3531, University of Sheffield (Shef-
field, UK). Animal experiments carried out at the University of
Osaka were performed according to National Institutes of
Health institutional guidelines and Osaka University animal
experimental guidelines under approved protocols. Studies
were routinely inspected by the attending veterinarian to
ensure continued compliance with the proposed protocols.
Mice were maintained on a 12:12-h light/dark cycle, and auto-
claved water and mouse chow were provided ad libitum.
Lpar1/- andLpar3/-deficientmice originally generated in
a C57Bl/6 background were backcrossed more than 12 times
with BALB/c females (19, 30). Lpar2/ knock-out mice gen-
erated in a C57BL/6–129/SvJ background were described pre-
viously (29). Animals were genotyped by PCR following the
procedures described previously (19, 29, 30). CX3CR1-GFP
knock-in mice (41) were obtained from The Jackson Labora-
tory. Mutant mice were genotyped by PCR. BALB/c mice were
obtained from Janvier SA (Le Genest St. Isle, France). Female
BALB/c nude mice were obtained from Charles River (Kent,
UK).
Ovariectomy—Nine-week-old female BALB/c mice were
anesthetized by intraperitoneal injection of a xylazine (0.1%,
w/v)/ketamine (0.75%) mixture. After dorsal incision of the
abdominal wall, the ovaries were picked clean from the sur-
rounding fat tissue and removed (ovariectomy) or replaced
without injury (sham-operated mice). Animals were subjected
to daily intraperitoneal injections of risedronate (5 mg/kg) or
twice daily per os injection of Debio0719 (50 mg/kg) or vehicle
receptors 1–6; MCSF, macrophage-CSF; NFATc1, nuclear factor of acti-
vated T-cells cytoplasmic 1; OVX, ovariectomy; RANK-L, receptor-activated
nuclear receptor factor B ligand; TRAP, tartrate-resistant acid phospha-
tase; ANOVA, analysis of variance; PTH, parathyroid hormone; EGFP,
enhanced GFP; Oc.S, TRAP-positive trabecular bone surface; BS, bone
surface.
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(saline). Mice were euthanized 30 days after OVX. To confirm
the efficiency of OVX, uteri were removed and weighed at the
end of the experiments. Bones from all euthanized mice were
dissected out and used either for CT imaging or histological
analysis. Total RNA extraction from bone was carried out on
12-week-old female BALB/c nude mice (Charles River, Kent,
UK). On day 0, 18mice per group were injected with 100g/kg
zoledronic acid or 0.1 ml of saline intraperitoneally. Three days
after injection, nine mice from each group were either ovariec-
tomized or sham-operated before sacrifice on day 10. Tibiae
and femurs from three mice per group were pooled and flash-
frozen in liquid nitrogen.
Two-photon Intravital Bone Tissue Imaging—CX3CR1-EGFP
mice were subcutaneously administered either Debio0719 (20
mg/kg bodyweight) or vehicle (DMSO inPBS). Four hours after
administration, bone tissues of these mice were visualized to
measure the mobility of EGFP cells by intravital microscopy.
Experiments were carried out on mouse calvaria bone tissues
using a protocolmodified fromaprevious study (42).Micewere
anesthetized with isoflurane (Escain; 2.0% (v/v) vaporized in
100% (v/v) oxygen), and hair at the neck and scalp was removed
with hair removal lotion (Epilat). The frontoparietal skull was
exposed, and the mouse head was immobilized in a custom-
made stereotactic holder. The imaging systemwas composed of
a multiphoton microscope (A1-MP; Nikon) driven by a laser
(Chameleon Vision II Ti: Sapphire; Coherent) tuned to 880 nm
and an upright microscope (APO, N.A. 1.1; Nikon) equipped
with a 25 water immersion objective (HCX APO, N.A. 1.0;
Leica). The microscope was enclosed in an environmental
chamber in which anesthetized mice were warmed by heated
air. Fluorescent cells were detected through a bandpass emis-
sion filter at 525/50 nm (for EGFP). Vessels were visualized by
injecting 70 kDa of Texas red-conjugated dextran (detected
using a 629/56 nm filter) i.v. immediately before imaging. Image
stacks were collected at a 5-m vertical step size at a depth of
100–150mbelow the skull bone surface. The time resolution
was 1 min. Raw imaging data were processed with Imaris (Bit-
plane) with a Gaussian filter for noise reduction. Automatic
three-dimensional object tracking with Imaris Spots was aided
withmanual corrections to retrieve cell spatial coordinates over
time.
Three-dimensional CT—Microcomputed tomography ana-
lyseswerecarriedoutusingaCTscannerSkyscan1174 (Skyscan;
Kontich,Belgium).Thex-ray tubewas set to a voltageof 50kVand
a current of 800 mA. A 0.5-mm aluminum filter was used to
reduce beam-hardening artifacts. Sampleswere scanned in 70%
ethanol with a voxel size of 10.3 m. For each sample, 265
section images were reconstructed with NRecon software (ver-
sion 1.6.1.8, Skyscan). Three-dimensional modeling and analy-
sis of bone volume/trabecular volume, were obtained with the
CTAn (version 1.9, Skyscan) and CTVol (version 2.0, Skyscan)
software. The dissected bones were then processed for histo-
logical analysis.
Bone Histology—Hind limbs were fixed, decalcified with 16%
EDTA, and embedded in paraffin. Five-m tissue sections were
stained with Goldner’s Trichrome and processed for histomor-
phometric analysis. In situ detection of osteoclasts was carried
out on tissue sections using the tartrate-resistant acid phospha-
tase (TRAP) activity kit assay (Sigma). The resorption surface
(Oc.S/BS) was calculated as the ratio of TRAP-positive trabec-
ular bone surface (Oc.S) to the total trabecular bone surface
(BS) using the computerized image analysis system Morpho-
Expert (Exploranova).
Osteoclastogenesis Assay—Bone marrow cells from hind
limbs of 6-week-old male mice were collected and seeded in
12-well tissue culture plates at a density of 2 105 cells per well
in -minimal essential medium (Invitrogen) supplemented
with 10% v/v FBS (Life Technology, Saint Aubain, France), 1%
penicillin/streptomycin (Life Technology), 1% L-glutamine
(Sigma), 25 ng/ml macrophage-CSF (R&D Systems, Lille,
France), 100 ng/ml receptor-activated nuclear receptor factor
B ligand (RANK-L). Culture media were then supplemented
with or without Ki16425 (10 M), Debio0719 (1 M), or
VPC12249 (10 M). After 6 days, mature osteoclasts were enu-
merated under a microscope on the basis of the number of
nuclei (n 3) and the TRAP activity (Sigma). Results were
expressed as the number of osteoclasts per well.
Podosome Belt and Sealing Zone Quantification—Osteo-
clasts in culture on glass coverslips were fixed in 4% parafor-
maldehyde, pH 7.2, for 10 min, permeabilized with 0.2% Triton
X-100 in PBS for 5 min, then saturated with 2% BSA in PBS,
followed by incubation with rhodamine-conjugated phalloidin
to reveal F-actin. Osteoclasts in culture on bovine cortical bone
sliceswere fixedwith 4%paraformaldehyde in PBS for 10min at
37 °C and permeabilized using PBS  0.2% Triton X-100 in
PBS. Then cells were incubated for 20 min with Alexa Fluor
488 phalloidin (Invitrogen) diluted 1:100. Image acquisition
was performed with an inverted confocal microscope Zeiss
LSM780 using GaAsP PMT and an EC-Plan-Neofluar 20/0.5
objective. The surface areawasmeasuredmanuallywith ImageJ
software.
Resorption Assay—Osteoclast efficacy to resorb mineralized
matrixwas carried out using apatite collagen complex (Corning
Glass). Two hundred osteoclasts of each genotype were plated
in each well and left to resorb for 48 h. Cells were removed by a
gentle shaking in 0.001% Triton buffer lysis for 1 h; the matrix
was stained with silver nitrate, and the resorption pits were
detected under a light microscope. To measure the resorbed
surface area, a series of 99 micrographs were imaged using a
DMI system, and the mosaic of each well was reconstituted
using a plugin of ImageJ software. The pit surface per single
osteoclast was quantified with ImageJ, and data were reported
as resorbed mineralized surfaces in m2/Oc. Alternatively, an
equivalent number of pre-osteoclasts isolated from WT
BALB/c mice were cultured for 4 days. Then the culture media
was supplemented with Ki16425 (10 M) for an additional 3
days. The culturewas then stopped, andpit surfaceswere deter-
mined as described above.
Reverse Transcription and RT-PCR—Total RNAs from oste-
oclast cultures were extracted using Nucleospin RNAII kit
(Macherey-Nagel, Hoerdt, France) and from powdered whole
bone with TRIzol (Invitrogen). Complementary DNA from
osteoclasts and boneswere synthesized by reverse transcription
using iScript cDNA synthesis kit (Bio-Rad) and Superscript III
(Invitrogen), respectively. Expression of target genes was quan-
tified by real time quantitative RT-PCR on an Eppendorf Mas-
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tercycler RealPlex (Eppendorf, Sartrouville, France) using the
SYBR Green PCR kit (VWR International, Fontenay-Sous-
Bois, France) and sets of specific primers (Table 1). Quantifica-
tions were normalized to corresponding RNA L32 values and
expressed as relative expression using the 2(CT) method
(43).
Statistical Analysis—Differences between groups were
determined by one- or two-way ANOVA followed by Bonfer-
roni post-test using GraphPad Prism Version 5.0c software.
Single comparisons were carried out using two-sided unpaired
t test. p 0.05 was considered significant.
RESULTS
Expression of LPA Receptors during Osteoclastogenesis—Os-
teoclastogenesis depends on a sequential gene activation pro-
gram controlling the proliferation of osteoclast precursors that
successively fuse to form large polykaryons that eventually dif-
ferentiate into fully active multinucleated osteoclasts (44). Pri-
mary culture of bone marrow cells (BMCs) extracted fromWT
BALB/c mice in the presence of MCSF and RANK-L was per-
formed. In agreement with previous reports showing high
expression levels of LPA6(P2Y5) in hematopoietic cells and
during monocyte-to-macrophage differentiation (45), we
found by real time PCR (Fig. 1A) that LPA6 had the highest
expression levels in BMCs (data not shown) and at day 1 of
osteoclastogenesis that decreased to high and stable values
from days 2 to 5. LPA3 was not detected in osteoclast progeni-
tors and during osteoclastogenesis, whereas LPA1 expression
prevailed among all other LPA receptors at both early (days
1–3) and late (days 3–5) stages of osteoclast differentiation.
Also, LPA1, LPA2, LPA4, and LPA5 were up-regulated from
days 3 to 4 concomitantly with the expression of osteoclast
differentiation markers (ATP6v0d2, integrin 3 (Beta3), calci-
tonin receptor (CTR), and cathepsinK (CTSK)) (Fig. 1B). These
data suggest that LPA1 and LPA6 potentially regulate the
behavior of both osteoclast precursors and mature osteoclasts,
whereas the activity of other LPA receptors might only play a
role during the latter stages of osteoclast differentiation.
Inhibiting LPA1 Activity Impairs Osteoclastogenesis—To
determine the role of LPA receptors in osteoclastogenesis, pri-
mary cultures of BMCs collected from Lpar1/, Lpar2/,
and Lpar3/mice andWT littermates were performed in the
presence of MCSF and RANK-L. After 6 days, we found that
the number of tartrate-resistant acid phosphatase (TRAP)-pos-
itive multinucleated cells (mature osteoclasts) from Lpar1/
mice was significantly lower by 62% to that obtained with WT
cells (316 82.2 and 831 78.6, p 0.001) (Fig. 1,C andD). In
marked contrast, the numbers of mature osteoclasts generated
from Lpar2/ and Lpar3/ mice were identical to those
obtained fromWTcells withmatched genetic background (Fig.
1,C andD). Inhibition of osteoclast differentiation in Lpar1/
cells was confirmed at the transcriptomic level, because the
expression of osteoclast markers wasmarkedly decreased com-
pared with WT cells (Fig. 1E). Altogether these results suggest
the implication of LPA1 in osteoclast differentiation, although
LPA2 or LPA3 appear not to be involved. Hematopoietic oste-
oclast precursors, monocytes, do not express LPA3 (46, 47).
Because our previous observations showed no LPA3 expression
at all stages of osteoclastogenesis (Fig. 1A), we next considered
cells from the osteoclast lineage as LPA3-null cells. Thus, to
further investigate the role of LPA1 in osteoclast differentiation,
we decided to use a pharmacological approach to inhibit LPA1
activity. We treated BMC precursors with nonspecific LPA1/
TABLE 1
List of specific primer sets
F is forward, and R is reverse.
Name Sequence 5–3 °C Slope Intercept
LPA1-F CCAGGAGGAATCGGGACAC 63 3.48 20.52
LPA1-R CAATAACAAGACCAATCCCGGA
LPA2-F GTCAAGACGGTTGTCATCATTCT 67 3.27 25.07
LPA2-R GAAGCATGATCCGCGTGCT
LPA3-F ACAAAGCTTGTGATCGTCCTGT 63 3.223 22.78
LPA3-R TCATGATGGACATGTGTGTTTCC
LPA4-F GCATTGTTGACATTAGTGGTGGA 63 3.256 26.46
LPA4-R AACCTGGCCCTCTCTGATTT
LPA5-F CCGTACATGTTCATCTGGAAGAT 63 3.747 24.60
LPA5-R CAGACTAATTTCTCTTCCCACCT
LPA6-F TGTTTCCAACTGCTGCTTTG 58 3.535 22.75
LPA6-R GAGCAGTCCCAGTGGCTTAG
Beta-3-F GATGACATCGAGCAGGTGAAAGAG 67 3.137 21.42
Beta-3-R CCGGTCATGAATGGTGATGAGTAG
CTR-F AGCCACAGCCTATCAGCACT 67 3.546 17.52
CTR-R GTCACCCTCTGGCAGCTAAG
CTSK-F GAGGGCCAACTCAAGAAGAA 65 2.972 18.89
CTSK-R GCCGTGGCGTTATACATACA
ATP6v0D2-F TCAGATCTCTTCAAGGCTGTGCTG 67 3.718 17.52
ATP6v0D2-R GTGCCAAATGAGTTCAGAGTGATG
cFMS-F AACATATGGACTTCGCCCTC 65 3.34 13.20
cFMS -R CTAGCACTGTGAGAACCCCA
NFATc1-F GGTCTTCCGAGTTCACATCC 60 3.595 14.38
NFATc1-R GCCTTCTCCACGAAAATGAC
c-Fos-F CCGCATGGAGTGTGTTGTTCC 67 3.594 14.10
c-Fos-R GACCACCTCGACAATGCATGA
DC-STAMP-F GGGCACCAGTATTTTCCTGA 60 3.644 16.04
DC-STAMP-R CAGAACGGCCAGAAGAATGA
L32-F CAAGGAGCTGGAGGTGCTGC 60 4.071 12.61
L32-R CTGCTCTTTCTACAATGGC
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LPA3 antagonists (Ki16425, Debio0719, and VPC12249). Each
LPA1 inhibitor reduced MCSF/RANK-L-induced osteoclasto-
genesis of WT BMC precursors by 55% (VPC12249), 68%
(Ki16425), or 83% (Debio0719) (Fig. 2A). Interestingly, the
extent of inhibition caused by LPA1 antagonists was not statis-
tically significantly different to that observed with Lpar1/
BMCs (62%) (Fig. 2A). As presented above (Fig. 1A), LPA2 was
also up-regulated during osteoclastogenesis; therefore, we
investigated whether blocking of both LPA1 and LPA2 activity
would inhibitosteoclastogenesis toa furtherextent.Wefoundthat
supplementingLpar2/BMCculturemediawithKi16425 inhib-
ited the differentiation of osteoclasts by 62% (Fig. 2B), which was
FIGURE 1. Impaired osteoclast differentiation in culture of Lpar1/ but not Lpar2/ and Lpar3/ bonemarrow cells. A, time course of expression of
LPA receptors (LPA1–6); B, ATP6v0d2, Beta3, CTR, and CTSK mRNA in bone marrow cell from wild type BALB/c mice cultured with serumMCSF RANK-L.
Values were normalized to housekeeping L32 gene. All values were the mean  S.D. of three experiments. C, micrographs of bone marrow cells from LPA
receptormutants (/), heterozygous (/), andwild type (WT)mice fromBALB/c andC57Bl/6–129/SvJ backgrounds, grownwith serumMCSF RANK-L
and stained for TRAPactivity (TRAP).D,numberof TRAPmultinucleatedcells perwell. All values are themeanS.D. of 4–8experiments. ***,p0.001 versus
WT BALB/c bone marrow cells using one-way ANOVA with a Bonferroni post-test. Bar scale represents 100 m. veh, vehicle. E, time course of expression of
ATP6v0d2, Beta3, CTR, andCTSKmRNA in bonemarrow cells fromwild type BALB/c (open symbols) and Lpar1/mice culturedwith serumMCSF RANK-L.
Values were normalized to housekeeping L32 gene. All values were themean S.D. of three experiments. †, p 0.05; ††, p 0.01; †††, p 0.001; versuswild
type cells using two-way ANOVA with a Bonferroni post-test. D, day.
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not significantly different from the inhibition of osteoclast forma-
tion caused by Ki16425 treatment of WT BMCs (69%, Fig. 2A).
This result indicates that blocking of both LPA1 and LPA2 activity
does not inhibit osteoclastogenesis to a greater extent than that
achieved by blocking LPA1 alone.
We next investigated whether LPA1 plays a role in a particu-
lar phase of osteoclastogenesis (proliferation, fusion, and differ-
entiation). We found that a short treatment period with
Ki16425 during the proliferation phase of osteoclast precursors
(days 1–3 and days 2 and 3), or during the late phase of mature
osteoclast differentiation (days 5–7), did not significantly affect
the final number of osteoclasts (Fig. 3, A and B). In contrast,
when added during the fusion phase of osteoclast precursors
(days 3–4, 3–5, and 4–5), Ki16425 significantly inhibited the
formation of osteoclasts by 48% at days 3–5 (p  0.001) and
days 4 and 5 (p 0.001) and by 58% at days 3 and 4 (p 0.001))
compared with vehicle-treated BMCs (Fig. 3, A and B). Addi-
tionally, the levels of inhibition were not statistically signifi-
cantly different from the 69% inhibition of osteoclastogenesis
resulting from addition of Ki16425 from days 1 to 7. When
added between days 3 and 5, Ki16425 also significantly induced
an accumulation of osteoclasts with a low number of nuclei
(3 n5) compared with vehicle-treated cells (73 versus 40%;
p  0.05) and a decrease in the number of osteoclasts with a
high number of nuclei; 5 n10 and n10 (25% versus 50%;
p  0.001) and (2% versus 10%; p  0.05), respectively. Also, a
significant accumulation by 69% (p 0.05) of osteoclasts with
low number of nuclei (3  n 5) was observed in Lpar1/
BMC cultures. Altogether, these results indicated that blocking
LPA1 activity inhibited the fusion of osteoclast precursors (Fig.
3C). In agreement with previous observations on Lpar1/
BMCs, inhibiting LPA1 activity with Ki16425 significantly
decreased the expression of markers of osteoclast activity
(ATP6v0d2, CTR, Beta3, and CTSK) (Fig. 3D). In addition,
comparedwith vehicle, Ki16425 hadno effect on the expression
of LPA1, the transcription factor c-Fos, and theMCSF receptor
cFMS that are expressed at the early stage of osteoclast differ-
entiation, whereas expressions of the pro-survival NFATc1 and
the fusion protein DC-STAMP that are implicated in fusion
and differentiation were significantly decreased by 50% (p 	
0.003) and 70% (p	 0.021), respectively (Fig. 3D).
Inhibiting LPA1 Activity Impairs the Cytoskeletal Organiza-
tion in Mature Osteoclasts—Osteoclastic bone resorption
activity is dependent on a highly specialized organization of the
FIGURE2.Antagonistsof LPA1 impair osteoclastdifferentiation fromprimary culturebonemarrowcell culture.A, visualizationof TRAP
multinucleated
osteoclasts obtained fromwild type BALB/cmice grownwith serumMCSF RANK-L in the presence of vehicle (WTVeh) or Ki16425 (10M), Denio0719 (1
M), or VCP12249 (10M) (upper panels) and evaluation of number of TRAPmultinucleated cells in % of vehicle-treated cells (lower panel). B,micrographs of
bonemarrowcells fromwild typeC57Bl/6–129/SvJ (C57Bl/6) or Lpar2/micegrownwith serumMCSFRANK-L in thepresenceof vehicle (WT) or Ki16425
(10M) and stained for TRAP activity (upper panels). Number of TRAPmultinucleated cells in%of vehicle-treated cells (lower panel). All values are themean
S.D. of 3 to 4 experiments. **, p 0.01; ***, p 0.001 versus vehicle-treated cells with the same genotype using one-way ANOVAwith Bonferroni post-test. Bar
scales, 100 m.
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FIGURE 3. Inhibition of LPA1 activity impairs osteoclast fusion. A, schematic representation of treatment schedule of bone marrow cells from wild type
BALB/c mice grown with serumMCSF RANK-L in the absence (dotted lines) or presence of Ki16425 (bold lines) (upper panel). Micrographs of cells stained
for TRAP activity (lower panels). Prolif, proliferation; Diff, differentiation. B, number of TRAPmultinucleated cells in % of vehicle-treated cells. ***, p 0.001
versus vehicle-treated cells using one-way ANOVA with Bonferroni post-test. C, repartition of osteoclasts number in Ki16425- versus vehicle-treated cells with
Ki16425 according to the number of nuclei. D, real time PCR analysis of LPA1, NFATc1, c-Fos, c-Fms, DC-STAMP, ATP6v0d2, CTR, Beta3, and CTSK mRNA
expression in bonemarrow cells cultured for 6 days in presence of vehicle (Veh) or Ki16425. Values are normalized to housekeeping gene L32. All values are the
mean S.D. of three experiments. ¶, p 0.05; ¶¶, p 0.01 versuswild type osteoclasts using two-sided unpaired t test. Bar scale, 100 m. D, day.
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actin cytoskeleton (48). Because induction of cytoskeletal rear-
rangements is a hallmark of LPA activity (49), we investigated
the role of LPA1 in osteoclast actin cytoskeleton organization.
Mature osteoclasts from BMCs of Lpar1/ and WT animals
were generated on glass coverslips and stained with rhoda-
mine-phalloidin. The number of osteoclasts with a complete
podosome belt was determined by epifluorescencemicroscopy.
We found that the proportion of Lpar1/ osteoclasts with a
complete podosome belt was significantly lower than that of
WT osteoclasts (35% versus 58%; p  0.001) (Fig. 4A). This
experiment was repeated with WT cells seeded on bovine cor-
tical bone slices. Under these conditions, osteoclasts form a
complex podosome belt-like structure rich in F-actin named
the sealing zone, which is required for successful osteoclastic
bone resorption (48).We observed that within 30min, Ki16425
(10 M) reduced the percentage of osteoclasts with detectable
sealing zone by 48.6% as a consequence of a decrease in the
percentage of osteoclasts with both complete (8% versus 25.6%;
p  0.001) and discontinued sealing zones (48% versus 74.4%;
p 0.05) (Fig. 4B). Moreover, Ki16425 decreased the area cov-
ered by the sealing zone in each osteoclast by 40.2% (Fig. 4B).
These results suggest that inhibition of LPA1 activity might
reduce the capacity of osteoclasts to adhere to the bone matrix,
impairing the formation of a fully efficient sealing zone and
hence inhibit bone resorption.
Inhibiting LPA1 Activity Impairs Osteoclast Bone Resorption
Activity—To analyze the role of LPA1 in osteoclast bone
resorption activity, we first generatedWT and Lpar1/ osteo-
clasts from BMCs on conventional culture plates, detached the
multinucleated cells, and seeded the same number of osteo-
clasts on mineralized tissue culture plates (apatite collagen
complex).We then imaged and quantified the resulting lacunae
by phase contrast microscopy. Themean resorbedmineral sur-
faces generated by Lpar1/ osteoclasts was significantly lower
compared with that ofWT osteoclasts (1190 222 m2 versus
329  81 m2; p 	 0.0013) (Fig. 5A). Treatment of WT oste-
oclasts with Ki16425 (10 M) reduced the mean resorbed min-
eral surface area by 60% (2413  402 m2 versus 946  118
m2; p 	 0.005) (Fig. 5B). Additionally, 72 h of treatment of
mature WT osteoclasts generated on dentin slices with
Ki16425 caused a 26% decrease in the density of osteoclasts
(542 23.1 versus 400 31.8 per cm2;p	 0.01)with noticeable
overspreading of Ki16425-treated osteoclasts attached to the
dentin (Fig. 5C). These results indicate that LPA1 is essential for
optimal bone resorption and that blocking LPA1 activity might
reduce the tight adhesion of osteoclasts to the mineralized
matrix required for resorption activity.
Inhibition of LPA1 Activity Prevents Osteoclast-induced Can-
cellous Bone Loss—Decreased levels of estrogen are responsible
for osteoporosis mediated by increased osteoclast activation
and excessive bone loss in postmenopausal women. Osteopo-
rosis can bemimicked in animals byOVX (50). Fourweeks after
surgical intervention, we collected distal femur and tibia
metaphyses of ovariectomized and sham mice, extracted total
bone RNAs, andmeasured expression of LPA receptors by RT-
quantitative PCR. Expression of LPA6 was predominant in the
bone of sham-operated mice, whereas LPA1, LPA3, PLA4, and
LPA5 were found at lower levels, and LPA2 was barely detectable
(Fig. 6). Following OVX, the expression of LPA6 was not signifi-
cantly modified, whereas LPA1 was dramatically increased
(11.3-fold) and LPA4 to a lesser extent (1.7-fold), although
FIGURE 4.Blocking LPA1 activity interfereswith podosomebelt and seal-
ing zone organizations. A, micrographs of mature osteoclasts (Oc) from
Lpar1/ andwild type (WT)mice seededonglass coverslips and stainedwith
rhodamine-conjugated phalloidin (left panels). Percentage of osteoclasts
with completepodosomebelts (right panels)Bar scale,200m.¶¶¶,p0.001
versuswild typeosteoclasts using two-sidedunpaired t test.B,micrographsof
mature osteoclasts fromwild typemice seeded on bone slices and incubated
with Ki16425 (10 M) for 0, 30, and 60 min and stained with Alexa Fluor 488
phalloidin (upper panels). Percentage of osteoclasts with sealing zones (SZ),
with complete sealing zone, and with discontinued sealing zone, and area of
sealing zone per osteoclast (lower panels). *, p  0.05; **, p  0.01, ***, p 
0.001 versus 0-min-treated cells using one-way ANOVAwith Bonferroni post-
test. Arrowheads indicate osteoclasts with a complete sealing zone. Arrows
indicate osteoclasts with discontinued sealing zones. Bar scale, 100 m.
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other receptors were down-regulated compared with sham-oper-
ated animals: LPA3 (7.1-fold) and LPA5 (35.5-fold) (Fig. 6A).
As expected, osteoclast activationmarkers (CTR andCTSK)were
up-regulated in bone following OVX due in part to an increase in
osteoclast differentiation (Fig. 6B). Remarkably, alongwith reduc-
ing the expression of osteoclastmarkers, the anti-resorptive agent
zoledronic acid inhibited up-regulation of LPA1 in the bone of
ovariectomized animals (Fig. 6B). These results indicate that
increased osteoclastic bone resorption in vivo is associated with
up-regulation of LPA1.
We next investigated the contribution of LPA1 during the
process of hyper-resorptive bone loss in vivo. Nine-week-old
female mice were ovariectomized and treated daily for 4 weeks
with vehicle or the Ki16425 structurally related LPA1 antago-
nist Debio0719 (20 mg/kg) (38) or the anti-resorptive agent
risedronate (4 mg/kg). We used CT imaging analyses of the
distal femurs to assess histomorphometric parameters of the
trabecular bone. As expected, risedronate treatment inhibited
trabecular bone loss, resulting in a bone volume/trabecular vol-
ume value not significantly different from that of sham-oper-
ated animals (23% 2.0 versus 26% 3.5) (Fig. 7A). Although
the bone volume/trabecular volume value in animals treated
with Debio0719 was lower than in sham mice, it was signifi-
cantly higher than in OVX animals treated with vehicle (19%
3.1 versus 14% 4.1; p 0.05) (Fig. 7, A and B). Overall, these
data indicate that systemic treatment of animals with the LPA1
antagonist Debio0719 prevented by 60% trabecular bone loss
induced by OVX.
Serum bone resorption markers are known to gradually
increase during the first 2 weeks following OVX and then rap-
idly return to base line the week after (51). Therefore, 4 weeks
after OVX, osteoclast activity in the bone of animals treated
with Debio0719 was analyzed by histological examinations of
tissue sections of tibia epiphyses stained for TRAP activity. As
expected, risedronate treatment completely blocked the OVX-
induced increase in osteoclast number (Oc.S/BS) (Fig. 7B).
There was no significant difference in Oc.S/BS ratio in animals
treatedwithDebio0719 comparedwith the sham group (28.2
4.5% versus 28.7 4.8%). Altogether, these results indicate that
systemic treatment with Debio0719 inhibited bone resorption
through a mechanism involving impairment of the differentia-
tion and/or the recruitment of osteoclast precursors at the bone
surface.
Inhibiting LPA1 Activity Impairs the Dynamic Behavior of
Circulating Osteoclast Precursors—To investigate the role of
LPA1 on osteoclast precursor migration in vivo, we performed
intravital two-photon imaging of calvaria from CX3CR1-
EGFPmice, examining the migratory behavior of fluorescent
monocytoid cells containing osteoclast precursors resident in
the marrow spaces. First, we measured the expression of
mRNAs encoding different LPA receptors in CX3CR1 oste-
oclast precursor monocytes. CX3CR1 cells from BMCs were
collected using a cell sorter and analyzed by RT-PCR. In agree-
ment with the results presented above, we found that LPA1,
LPA2, LPA4, LPA5, and LPA6were expressed inCX3CR1 oste-
oclast precursors, whereas LPA3 expression was not detectable
FIGURE 5.Blocking LPA1 activity inhibits osteoclast resorption. A,micrographs ofmineralizedmatrix apatite collagen complex incubated for 48hwithmature
osteoclasts from Lpar1/ or wild type (WT) mice (left panels). Resorbedmineral surface areas are shown in the right panes. ¶¶, p 0.01 versuswild type osteoclasts
using two-sidedunpaired t test.B,micrographsofmineralizedmatrix apatite collagencomplex incubated for 48hwithmatureosteoclasts fromwild typemice in the
presenceorabsenceKi16425 (10M) (left panels). Resorbedmineral surfaceareasare shown in the rightpanel. ¶¶,p0.01versusvehicle-treatedcellsusing two-sided
unpaired t test.C,micrographsof TRAP-stainedosteoclastsdifferentiatedonboneslices treatedwithvehicleorKi16425 fromdays4 to7 (left panels).Osteoclastswere
highlightedwith yellowdotted lines. Osteoclast numbers perm2of bone slice in thepresenceor absenceof Ki16425 are shown in the right panel. ¶¶,p 0.01 versus
vehicle (veh)-treated cells using two-sided unpaired t test. Bar scales, 100m in A and B and 50m in C.
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(Fig. 8A). Next we examined the effect of Debio0719 on the
mobility of osteoclast precursors in live bone tissues by using
intravital multiphoton microscopy (42). CX3CR1-EGFP mice
were administeredwith either Debio0719 (20mg/kg) or vehicle
s.c., and bone tissues were visualized tomeasure themobility of
EGFP cells 4 h later (Fig. 8B and supplemental video 1 and
video 2). The mean tracking velocity of CX3CR1-EGFP circu-
lating osteoclast precursors was significantly increased in mice
treated with Debio0719 (Fig. 8C) suggesting decreased recruit-
ment of osteoclasts at the bone surface because of increased
osteoclast precursors mobility in the marrow. Therefore, LPA1
may contribute to retaining circulating osteoclast precursors in
bone marrow cavity.
DISCUSSION
Bone remodeling controls bonemass through a complex reg-
ulation of the balance between bone formation mediated by
osteoblasts and bone resorption through osteoclast activity (1).
Here, we demonstrate that Lpar1/ animals also display
altered osteoclast differentiation and activity, indicating that
LPA/LPA1 pathway plays a central role in bone remodeling and
the interplay between osteoblasts and osteoclasts.
LPA is a serum-borne factor required for MCSF/RANK-L-
induced osteoclastogenesis of BMCs (52). Compared with pre-
vious reports describing the role of LPA on osteoclast function,
our in vitro experiments were carried out in the presence of
serum, avoiding potential LPA-independent serum stress sig-
nals on osteoclast primary culture cells. Incubating mature
osteoclasts for 12 h in serum-free medium induces apoptosis
that is rescued by addition of LPA, demonstrating that LPA is
an osteoclast survival factor (8). However, the role of LPA in
bone resorption is quite controversial and not well character-
ized to date. In vitro, LPA is shown to increase the bone resorp-
tion activity of rabbit osteoclasts but to cause a significant
reduction of pits formed of mouse osteoclasts (8, 53). In our
study, we found that supplementation of serum-containing
medium with Ki16425 inhibited complete sealing zone forma-
tion and decreased resorption activity in mouse osteoclasts,
indicating that through activation of LPA1, LPA promoted
bone resorption. Sealing zones are dynamic structures delineat-
ing compartments in which protons and proteases are secreted
by osteoclasts to dissolve and degrade the mineralized matrix
(48). Sealing zones are found inmyeloid cells and are composed
of cytoskeletal structures, named podosomes, that relate to
stress fibers and focal adhesions in mesenchymal cells sharing
similar regulation via Rho GTPases (54). LPA1 was primarily
identified for its capacity to induce cytoskeleton rearrangement
and cell contraction through a mechanism involving G12/13
and downstream activation of RhoA (20, 55). Therefore, acting
through RhoA, LPA1 may likely control complete sealing zone
formation, resulting in decreased resorption activity as
observed on WT osteoclasts treated with Ki16425. Mature
Lpar1/ osteoclasts showed a significant reduction of podo-
some belt formation and a decrease in the extent of mineral
resorption, demonstrating that in the presence of serum LPA1
controls osteoclastic bone resorption.
Increased cell survival, proliferation, and motility are hall-
marks of LPA effects on a large range of cell types (56). Cells
commonly co-expressmultiple LPA receptors, and defining the
ones that are involved in specific functions remains challeng-
ing. Transcripts encoding LPA1, LPA2, LPA4, and LPA5 are
present inmature osteoclasts (8).We found expression of LPA1
at all stages of osteoclast differentiation that was further up-
FIGURE 6. LPA1 is up-regulated in bones of ovariectomized mice. A, real
time PCR analysis of LPA receptor (LPA1–6) mRNA expression in bone of OVX-
and sham-operated mice. Values are the mean S.D. of three mice normal-
ized to housekeeping gene L32. ¶, p 0.05; ¶¶, p 0.01; ¶¶¶, p 0.001 versus
SHAM-operated animals using two-sided unpaired t test. B, real time PCR
analysis of LPA1, CTR, and CTSKmRNA expression in bone of OVX- and sham-
operated mice and ovariectomized mice treated with zoledronic acid (100
g/kg) (OVXZol). Values are the mean  S.D. of three mice normalized to
housekeeping gene L32. All values are the mean S.D. of three mice. *, p
0.05; ***, p  0.01 versus SHAM-operated animals. ANOVA with Bonferroni
post-test.
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regulated together with LPA2, LPA4, and LPA5 concomitantly
with the fusion and differentiation phases of osteoclast precur-
sors.Lpar2/BMCshadnot altered osteoclastogenesis capac-
ity, suggesting that LPA2 may not contribute to bone remodel-
ing via osteoclast activity. The role of LPA4, LPA5, and LPA6 in
osteoclast function remains to be established. LPA1 transduces
the mitogenic activity of LPA in fibroblasts and cancer cells
(57–60). Proliferation of osteoclast precursors is a prerequisite
for successful osteoclastogenesis (44). Treatment of BMCswith
Ki16425 during the proliferation phase of osteoclast progeni-
FIGURE 7. Inhibition of LPA1 activity prevents OVX-induced bone loss. A, two-dimensional longitudinal (upper panels) and transversal (lower panels)
sections of femurs of 9-week-old OVX or sham-operated BALB/cmice treated with vehicle (Veh), risedronate (Rise), or Debio019 (Debio).Dotted lines indicated
epiphysis transversal section location. B, trabecular bone volume in femurs of mice 4 weeks after surgical intervention. C,micrographs of TRAP-stained tibia
sections of shamorOVXmice treatedwith vehicle, risedronate, or Debio019. Red arrows indicate bone-lining osteoclasts.D,histomorphometric assessment of
the resorption surface (Oc.S/BS) of animals in eachgroup.All values are themeanS.D. of 6–8mice. *,p0.05; **,p0.01; ***p0.001 versus vehicle-treated
OVXmice using one-way ANOVA with Bonferroni post-test. Bar scale, 250 m.
FIGURE 8. Effect of LPA1 activity inhibition on the motility of osteoclast precursors in bone. A, expression of mRNA of LPA receptors in CX3CR1
 cells.
CX3CR1
 cells frombonemarrow in CX3CR1-EGFPmicewere sorted by FACS Aria, and RT-PCRwas performed to detect LPA receptor and GAPDH expressions.
Panel a, total complementary DNA isolated frommouse brain was used as a positive control (panel b). B, intravital multiphoton imaging of mouse skull bone
tissues of CX3CR1-EGFPmice, treated with either vehicle only (left panels; supplemental Video 1) or Debio0719 (right panels; supplemental Video 2). CX3CR1

cells appear green. Themicrovasculaturewas visualized by intravenous injection of Texas red-conjugated 70-kDa dextran (red). Blue indicates the bone surface
(upper panels). Themovements of CX3CR1
 cellswere tracked for 30min.Colored lines show the associated trajectories of cells (lower panels). Scale bars, 40m.
C, summary of the mean tracking velocity of CX3CR1-EGFP cells treated with vehicle (blue circle) and Debio0719 (red circle). Data points (n	 831 for vehicle-
treated; n	 1163 for Debio0719-treated) represent individual cells compiled from three independent experiments, and error bars represent S.E. ¶¶¶, p
0.001 versus vehicle-treated mice using two-sided unpaired t test.
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tors had no effect on the final number of mature osteoclasts,
indicating that LPA1 activity is not required for proliferation of
osteoclast precursors. In addition, expression of c-Fos and
c-Fms was not affected by Ki16425 treatment. RANK-L acti-
vates expression of c-Fos (61), and high concentrations of
MCSF acting through c-Fms restores the expression of c-Fos in
Beta3/ osteoclasts (62). Therefore, although LPA up-regu-
lates c-Fos in various cells (63), its expression in osteoclasts was
likely sustained by MCSF and RANK-L abundantly present in
BMC culture media independently of LPA action. LPA acti-
vates NFATc1 in osteoclasts and promotes survival (8).
Decreased expression of NFATc1 in BMCs treated with Ki16425
might decrease osteoclast precursor survival and differentiation
and together with decreased expression of the fusion protein
DC-STAMPcould be responsible for the observed decrease in the
fusion of osteoclast precursors.
LPA1 is themost ubiquitous LPA receptor (64). Expression of
LPA1 in bone cells is well documented (65). However, regula-
tion of LPA1 expression in bone is not known. OVX or contin-
uous exposure to elevated levels of PTH results in an increase in
bone resorption activity, hypercalcemia, and bone loss (66, 67),
whereas subcutaneous intermittent PTH administration
increases bone turnover and osteoblast activity resulting in net
anabolic effects on bone and reduced risk of fractures (68).
Lpar1 expression was not reported in the list of genes that were
modulated in the bones of animals treated with intermittent
administration of PTH (69), whereas Lpar1 was up-regulated
by 1.5-fold in the bone of rats treated with continuous infusion
of PTH(1–34) (70).We found Lpar1was up-regulated by 4-fold
in the bones of ovariectomized mice. These results strongly
support the link between LPA1 expression and osteoclast activ-
ity in vivo. Aminobisphosphonates (i.e. zoledronic acid and
risedronate) are powerful inhibitors of osteoclast activity and
thereby are the standard of care in patients with diseases asso-
ciated with excessive bone resorption, such as osteoporosis,
multiple myeloma, and bone metastases (71). Here, we showed
that zoledronic acid inhibited up-regulation of LPA1 in bones of
ovariectomized mice, confirming that modulation of LPA1
expression was linked to mature osteoclast activity. Blocking
LPA1 function in vivowith the LPA1 antagonist Ki16425 inhib-
its the progression of osteolytic bone lesions in mouse models
(72). The Ki16425 structurally related LPA1 antagonist,
Debio0719 (38), partially prevented bone loss induced by OVX
compared with complete bone loss prevention with risedro-
nate. Remarkably, Debio0719 was equally potent as risedronate
at inhibiting the increase of osteoclast number at the bone sur-
face of ovariectomized mice, but the underlying mechanisms
may be different. Nitrogen-containing bisphosphonates are
powerful inducers of apoptosis of osteoclasts due to inhibition
of farnesyl pyrophosphate synthase activity (73). In vivo, resorb-
ing osteoclasts undergo apoptosis due to uptake of bisphospho-
nate released from the bone surface. We demonstrate that
antagonists of LPA1 decreased in vitro osteoclast differentia-
tion and in vivo the number of osteoclasts lining on the surface
of trabecular bone of ovariectomized mice. Osteoclast precur-
sors are nonadherent circulating hematopoietic cells (44). In
vivo osteoclastogenesis depends on the recruitment and attach-
ment of osteoclast progenitors to the bone surface initiating
their fusion and subsequent differentiation. Our in vitro results
demonstrate that blocking the LPA1 pathway inhibits the
expression of osteoclast markers, including the adhesion mol-
ecule 3 integrin, and the fusion of osteoclast precursors, and
interferes with the cytoskeletal organization altering adhesion
of mature osteoclasts to mineralized surfaces. Debio0719
reduces the number of osteoclasts attached to the bone surface
in ovariectomized mice. The mode of action of Debio0719 in
vivo was not completely determined but may include the inhi-
bition of osteoclast differentiation and a decrease in the attach-
ment of osteoclast precursors to the bone matrix. A reduced
residence time of the nonadherent osteoclast progenitors at the
bone surface combined with an increased motility of CX3CR1-
GFPosteoclast precursorswould decrease the number of fusion
events and therefore the number of osteoclasts at the bone sur-
face. Subsequently, the number of nonadherent osteoclast pre-
cursors floating in bone marrow would be increased. This
hypothesis was supported by the increase in CX3CR1-GFP
nonadherent osteoclast progenitor mean tracking velocity in
the bonemarrow of animals treated with Debio0719. However,
the contribution of other LPA receptors (i.e. LPA4–6) to this
phenomenon remains to be established. Nevertheless, bone
mass recovery of ovariectomized mice treated with Debio0719
(50 mg/kg) was not complete. This may be a result of an inhib-
itory effect of the treatment on bone formation as the use of
LPA1 antagonists also inhibits osteoblast differentiation in vitro
(7, 74). Therefore, it is conceivable that systemic treatmentwith
Debio0719 may inhibit overall bone remodeling by affecting
both osteoclast and osteoblast function, thus decreasing bone
resorption while limiting bone formation.
Overall, our results demonstrate that LPA1 controls bone
remodeling by regulating directly osteoclastogenesis andmotil-
ity of osteoclast precursors in vivo and bone resorption. We
have shown previously that LPA1 is a potential target in the
context of osteolytic bone metastases (72). A recent work
showed that blocking LPA1 inhibits the development of arthri-
tis via cellular infiltration, Th17 differentiation, and osteoclas-
togenesis (75). Our study extends the field of applications of
anti-LPA1 therapy for patients suffering frombone fragility dis-
orders due to excessive bone resorption.
Acknowledgments—Debio0719 was generously provided by Debiop-
harmS.A. (Lausanne, Switzerland).We thank J.M.Vicat (Animalerie
Lyon Est Conventionnelle et Specific Pathogen Free (ALECS-SPF)
Animal Care Facility, UCBL, Lyon France) for technical support.
REFERENCES
1. Rodan, G. A., and Martin, T. J. (2000) Therapeutic approaches to bone
diseases. Science 289, 1508–1514
2. Jacobs, C. R., Temiyasathit, S., and Castillo, A. B. (2010)Osteocytemecha-
nobiology and pericellular mechanics. Annu. Rev. Biomed. Eng. 12,
369–400
3. Nakashima, T., Hayashi, M., and Takayanagi, H. (2012) New insights into
osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab. 23,
582–590
4. Takeda, S., and Karsenty, G. (2001) Central control of bone formation.
J. Bone Miner. Metab. 19, 195–198
5. Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K.,
Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., Nishina, H., Takeda, S.,
LPA1 in Osteoclast Activity
6562 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 10•MARCH 7, 2014
Takayanagi, H., Metzger, D., Kanno, J., Takaoka, K., Martin, T. J., Cham-
bon, P., and Kato, S. (2007) Estrogen prevents bone loss via estrogen re-
ceptor  and induction of Fas ligand in osteoclasts. Cell 130, 811–823
6. Houben, A. J., and Moolenaar, W. H. (2011) Autotaxin and LPA receptor
signaling in cancer. Cancer Metastasis Rev. 30, 557–565
7. Mansell, J. P., Nowghani, M., Pabbruwe, M., Paterson, I. C., Smith, A. J.,
and Blom, A.W. (2011) Lysophosphatidic acid and calcitriol co-operate to
promote human osteoblastogenesis: requirement of albumin-bound LPA.
Prostaglandins Other Lipid Mediat. 95, 45–52
8. Lapierre, D. M., Tanabe, N., Pereverzev, A., Spencer, M., Shugg, R. P.,
Dixon, S. J., and Sims, S. M. (2010) Lysophosphatidic acid signals through
multiple receptors in osteoclasts to elevate cytosolic calcium concentra-
tion, evoke retraction, and promote cell survival. J. Biol. Chem. 285,
25792–25801
9. Karagiosis, S. A., and Karin, N. J. (2007) Lysophosphatidic acid induces
osteocyte dendrite outgrowth. Biochem. Biophys. Res. Commun. 357,
194–199
10. Moolenaar, W. H. (2000) Development of our current understanding of
bioactive lysophospholipids. Ann. N.Y. Acad. Sci. 905, 1–10
11. Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993) The
bioactive phospholipid lysophosphatidic acid is released from activated
platelets. Biochem. J. 291, 677–680
12. Boucharaba, A., Serre, C.-M., Grès, S., Saulnier-Blache, J. S., Bordet, J.-C.,
Guglielmi, J., Clézardin, P., and Peyruchaud, O. (2004) Platelet-derived
lysophosphatidic acid supports the progression of osteolytic bone metas-
tases in breast cancer. J. Clin. Invest. 114, 1714–1725
13. Panupinthu, N., Rogers, J. T., Zhao, L., Solano-Flores, L. P., Possmayer, F.,
Sims, S.M., andDixon, S. J. (2008) P2X7 receptors on osteoblasts couple to
production of lysophosphatidic acid: a signaling axis promoting osteogen-
esis. J. Cell Biol. 181, 859–871
14. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T.,
Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N., and Chun, J. (2010) LPA
receptors: subtypes and biological actions.Annu. Rev. Pharmacol. Toxicol.
50, 157–186
15. Mutoh, T., Rivera, R., and Chun, J. (2012) Insights into the pharmacolog-
ical relevance of lysophospholipid receptors. Br. J. Pharmacol. 165,
829–844
16. Noguchi, K., Herr, D., Mutoh, T., and Chun, J. (2009) Lysophosphatidic
acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15–23
17. Choi, K.U., Yun, J. S., Lee, I. H., Heo, S. C., Shin, S.H., Jeon, E. S., Choi, Y. J.,
Suh, D. S., Yoon, M. S., and Kim, J. H. (2010) Lysophosphatidic acid-
induced expression of periostin in stromal cells: Prognostic relevance of
periostin expression in epithelial ovarian cancer. Int. J. Cancer 128,
332–342
18. Sims, S. M., Panupinthu, N., Lapierre, D. M., Pereverzev, A., and Dixon,
S. J. (2013) Lysophosphatidic acid: A potential mediator of osteoblast-
osteoclast signaling in bone. Biochim. Biophys. Acta 1831, 109–116
19. Contos, J. J., Fukushima, N.,Weiner, J. A., Kaushal, D., and Chun, J. (2000)
Requirement for the lpA1 lysophosphatidic acid receptor gene in normal
suckling behavior. Proc. Natl. Acad. Sci. U.S.A. 97, 13384–13389
20. Hecht, J. H.,Weiner, J. A., Post, S. R., and Chun, J. (1996) Ventricular zone
gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neu-
rogenic regions of the developing cerebral cortex. J. Cell Biol. 135,
1071–1083
21. Kingsbury, M. A., Rehen, S. K., Contos, J. J., Higgins, C. M., and Chun, J.
(2003) Non-proliferative effects of lysophosphatidic acid enhance cortical
growth and folding. Nat. Neurosci. 6, 1292–1299
22. Inoue, M., Rashid, M. H., Fujita, R., Contos, J. J., Chun, J., and Ueda, H.
(2004) Initiation of neuropathic pain requires lysophosphatidic acid re-
ceptor signaling. Nat. Med. 10, 712–718
23. Yung, Y. C., Mutoh, T., Lin, M. E., Noguchi, K., Rivera, R. R., Choi, J. W.,
Kingsbury, M. A., and Chun, J. (2011) Lysophosphatidic acid signaling
may initiate fetal hydrocephalus. Sci. Transl. Med. 3, 99ra87
24. Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M.,
Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart,
W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., and Luster, A. D. (2008)
The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to
lung injury by mediating fibroblast recruitment and vascular leak. Nat.
Med. 14, 45–54
25. Lin, S., Yeruva, S., He, P., Singh, A. K., Zhang,H., Chen,M., Lamprecht, G.,
de Jonge, H. R., Tse, M., Donowitz, M., Hogema, B. M., Chun, J., Seidler,
U., and Yun, C. C. (2010) Lysophosphatidic acid stimulates the intestinal
brush border Na/H exchanger 3 and fluid absorption via LPA(5) and
NHERF2. Gastroenterology 138, 649–658
26. Panchatcharam, M., Miriyala, S., Yang, F., Rojas, M., End, C., Vallant, C.,
Dong, A., Lynch, K., Chun, J., Morris, A. J., and Smyth, S. S. (2008) Lyso-
phosphatidic acid receptors 1 and 2 play roles in regulation of vascular
injury responses but not blood pressure. Circ. Res. 103, 662–670
27. Dusaulcy, R., Daviaud, D., Pradère, J. P., Grès, S., Valet, P., and Saulnier-
Blache, J. S. (2009) Altered food consumption in mice lacking lysophos-
phatidic acid receptor-1. J. Physiol. Biochem. 65, 345–350
28. Gennero, I., Laurencin-Dalicieux, S., Conte-Auriol, F., Briand-Mésange,
F., Laurencin, D., Rue, J., Beton, N., Malet, N., Mus, M., Tokumura, A.,
Bourin, P., Vico, L., Brunel, G., Oreffo, R. O., Chun, J., and Salles, J. P.
(2011) Absence of the lysophosphatidic acid receptor LPA1 results in
abnormal bone development and decreased bonemass.Bone 49, 395–403
29. Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura,
S., Brown, J. H., and Chun, J. (2002) Characterization of lpa(2) (Edg4) and
lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice:
signaling deficits without obvious phenotypic abnormality attributable to
lpa(2).Mol. Cell. Biol. 22, 6921–6929
30. Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner,M. K., Suzuki,
H., Amano, T., Kennedy, G., Arai, H., Aoki, J., and Chun, J. (2005) LPA3-
mediated lysophosphatidic acid signalling in embryo implantation and
spacing. Nature 435, 104–108
31. Ye, X., Skinner, M. K., Kennedy, G., and Chun, J. (2008) Age-dependent
loss of sperm production in mice via impaired lysophosphatidic acid sig-
naling. Biol. Reprod. 79, 328–336
32. Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F.,
Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., Iwata, C., Miyazono, K.,
Sakimura, K., Shimizu, T., and Ishii, S. (2010) LPA4 regulates blood and
lymphatic vessel formation during mouse embryogenesis. Blood 116,
5060–5070
33. Liu, Y. B., Kharode, Y., Bodine, P. V., Yaworsky, P. J., Robinson, J. A., and
Billiard, J. (2010) LPA induces osteoblast differentiation through interplay
of two receptors: LPA1 and LPA4. J. Cell. Biochem. 109, 794–800
34. Lin, M. E., Rivera, R. R., and Chun, J. (2012) Targeted deletion of LPA5
identifies novel roles for lysophosphatidic acid signaling in development
of neuropathic pain. J. Biol. Chem. 287, 17608–17617
35. An, S., Bleu, T., Hallmark, O. G., and Goetzl, E. J. (1998) Characterization
of a novel subtype of humanG protein-coupled receptor for lysophospha-
tidic acid. J. Biol. Chem. 273, 7906–7910
36. Heise, C. E., Santos, W. L., Schreihofer, A. M., Heasley, B. H., Mukhin,
Y. V., Macdonald, T. L., and Lynch, K. R. (2001) Activity of 2-substituted
lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a
LPA1/LPA3 receptor antagonist.Mol. Pharmacol. 60, 1173–1180
37. Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J.,
Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., Yagi, M., Sato, M.,
Suzuki, R., Murooka, H., Sakai, T., Nishitoba, T., Im, D. S., Nochi, H.,
Tamoto, K., Tomura, H., and Okajima, F. (2003) Ki16425, a subtype-se-
lective antagonist for EDG-family lysophosphatidic acid receptors. Mol.
Pharmacol. 64, 994–1005
38. David, M., Ribeiro, J., Descotes, F., Serre, C. M., Barbier, M., Murone, M.,
Clézardin, P., and Peyruchaud, O. (2012) Targeting lysophosphatidic acid
receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissem-
ination of breast cancer cells independently of cell proliferation and an-
giogenesis. Int. J. Oncol. 40, 1133–1141
39. Lee, C.W., Rivera, R., Gardell, S., Dubin, A. E., and Chun, J. (2006) GPR92
as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that in-
creases cAMP, LPA5. J. Biol. Chem. 281, 23589–23597
40. Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima,
Y., Taguchi, R., Shimizu, T., and Ishii, S. (2009) Identification and charac-
terization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol.
Chem. 284, 17731–17741
41. Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W.,
Sher, A., and Littman, D. R. (2000) Analysis of fractalkine receptor
LPA1 in Osteoclast Activity
MARCH 7, 2014•VOLUME 289•NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 6563
CX(3)CR1 function by targeted deletion and green fluorescent protein
reporter gene insertion.Mol. Cell. Biol. 20, 4106–4114
42. Ishii, M., Egen, J. G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y.,
Vacher, J., Proia, R. L., and Germain, R. N. (2009) Sphingosine-1-phos-
phate mobilizes osteoclast precursors and regulates bone homeostasis.
Nature 458, 524–528
43. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by
the comparative C(T) method. Nat. Protoc. 3, 1101–1108
44. Teitelbaum, S. L., and Ross, F. P. (2003) Genetic regulation of osteoclast
development and function. Nat. Rev. Genet. 4, 638–649
45. Lattin, J., Zidar, D. A., Schroder, K., Kellie, S., Hume,D.A., and Sweet,M. J.
(2007) G-protein-coupled receptor expression, function, and signaling in
macrophages. J. Leukocyte Biol. 82, 16–32
46. Fueller, M., Wang, D. A., Tigyi, G., and Siess, W. (2003) Activation of
humanmonocytic cells by lysophosphatidic acid and sphingosine-1-phos-
phate. Cell. Signal. 15, 367–375
47. Duong, C. Q., Bared, S.M., Abu-Khader, A., Buechler, C., Schmitz, A., and
Schmitz, G. (2004) Expression of the lysophospholipid receptor family and
investigation of lysophospholipid-mediated responses in human macro-
phages. Biochim. Biophys. Acta 1682, 112–119
48. Jurdic, P., Saltel, F., Chabadel, A., and Destaing, O. (2006) Podosome and
sealing zone: specificity of the osteoclast model. Eur. J. Cell Biol. 85,
195–202
49. Zhang, Q., Magnusson,M. K., andMosher, D. F. (1997) Lysophosphatidic
acid and microtubule-destabilizing agents stimulate fibronectin matrix
assembly through Rho-dependent actin stress fiber formation and cell
contraction.Mol. Biol. Cell 8, 1415–1425
50. Kalu, D. N. (1991) The ovariectomized rat model of postmenopausal bone
loss. Bone Miner. 15, 175–191
51. Rissanen, J. P., Suominen, M. I., Peng, Z., and Halleen, J. M. (2008) Se-
creted tartrate-resistant acid phosphatase 5b is a marker of osteoclast
number in human osteoclast cultures and the rat ovariectomy model.
Calcif. Tissue Int. 82, 108–115
52. David,M.,Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., Serre,
C. M., Grès, S., Bendriss-Vermare, N., Bollen, M., Saez, S., Aoki, J.,
Saulnier-Blache, J. S., Clézardin, P., and Peyruchaud, O. (2010) Cancer cell
expression of autotaxin controls bone metastasis formation in mouse
through lysophosphatidic acid-dependent activation of osteoclasts. PLoS
ONE 5, e9741
53. McMichael, B. K., Meyer, S. M., and Lee, B. S. (2010) c-Src-mediated
phosphorylation of thyroid hormone receptor-interacting protein 6
(TRIP6) promotes osteoclast sealing zone formation. J. Biol. Chem. 285,
26641–26651
54. Ory, S., Brazier, H., Pawlak, G., and Blangy, A. (2008) Rho GTPases in
osteoclasts: orchestrators of podosome arrangement. Eur. J. Cell Biol. 87,
469–477
55. Fukushima, N., Kimura, Y., and Chun, J. (1998) A single receptor encoded
by vzg-1/lpA1/edg-2 couples to G proteins andmediates multiple cellular
responses to lysophosphatidic acid. Proc. Natl. Acad. Sci. U.S.A. 95,
6151–6156
56. Moolenaar, W. H., Kranenburg, O., Postma, F. R., and Zondag, G. C.
(1997) Lysophosphatidic acid: G-protein signalling and cellular responses.
Curr. Opin. Cell Biol. 9, 168–173
57. Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., Stephens, C., Fang,
X., and Mills, G. B. (2008) Lysophosphatidic acid receptors determine
tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer
Inst. 100, 1630–1642
58. Daaka, Y. (2002) Mitogenic action of LPA in prostate. Biochim. Biophys.
Acta 1582, 265–269
59. Boucharaba, A., Guillet, B., Menaa, F., Hneino, M., van Wijnen, A. J.,
Clézardin, P., Philippe, C., Peyruchaud, O., and Oliver, P. (2009) Bioactive
lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast
cancer cell biological functions through distinct mechanisms. Oncol. Res.
18, 173–184
60. Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., and Tager, A.M.
(2013) LPA1-induced cytoskeleton reorganization drives fibrosis through
CTGF-dependent fibroblast proliferation. FASEB J27, 1830–1846
61. Takayanagi, H. (2007) Osteoimmunology: shared mechanisms and cross-
talk between the immune and bone systems. Nat. Rev. Immunol. 7,
292–304
62. Faccio, R., Takeshita, S., Zallone, A., Ross, F. P., and Teitelbaum, S. L.
(2003) c-Fms and the v3 integrin collaborate during osteoclast differ-
entiation. J. Clin. Invest. 111, 749–758
63. Spencer, J. A., and Misra, R. P. (1999) Expression of the SRF gene occurs
through a Ras/Sp/SRF-mediated-mechanism in response to serum
growth signals. Oncogene 18, 7319–7327
64. Lin, M. E., Herr, D. R., and Chun, J. (2010) Lysophosphatidic acid (LPA)
receptors: signaling properties and disease relevance. Prostaglandins
Other Lipid Mediat. 91, 130–138
65. Peyruchaud, O., Leblanc, R., and David, M. (2013) Pleiotropic activity of
lysophosphatidic acid in bone metastasis. Biochim. Biophys. Acta 1831,
99–104
66. Marx, U. C., Adermann, K., Bayer, P., Forssmann, W. G., and Rösch, P.
(2000) Solution structures of human parathyroid hormone fragments
hPTH(1–34) and hPTH(1–39) and bovine parathyroid hormone frag-
ment bPTH(1–37). Biochem. Biophys. Res. Commun. 267, 213–220
67. Wysolmerski, J. J. (2012) Parathyroid hormone-related protein: an update.
J. Clin. Endocrinol. Metab. 97, 2947–2956
68. Delmas, P. D., Vergnaud, P., Arlot,M. E., Pastoureau, P.,Meunier, P. J., and
Nilssen, M. H. (1995) The anabolic effect of human PTH(1–34) on bone
formation is blunted when bone resorption is inhibited by the bisphos-
phonate tiludronate–is activated resorption a prerequisite for the in vivo
effect of PTH on formation in a remodeling system? Bone 16, 603–610
69. Ferrari, S. L., Pierroz, D. D., Glatt, V., Goddard, D. S., Bianchi, E. N., Lin,
F. T.,Manen,D., andBouxsein,M. L. (2005) Bone response to intermittent
parathyroid hormone is altered inmice null for-arrestin2.Endocrinology
146, 1854–1862
70. Onyia, J. E., Helvering, L.M.,Gelbert, L.,Wei, T.,Huang, S., Chen, P., Dow,
E. R., Maran, A., Zhang, M., Lotinun, S., Lin, X., Halladay, D. L., Miles,
R. R., Kulkarni, N. H., Ambrose, E. M., Ma, Y. L., Frolik, C. A., Sato, M.,
Bryant, H. U., and Turner, R. T. (2005) Molecular profile of catabolic
versus anabolic treatment regimens of parathyroid hormone (PTH) in rat
bone: an analysis by DNA microarray. J. Cell. Biochem. 95, 403–418
71. Coleman, R. (2011) The use of bisphosphonates in cancer treatment.Ann.
N.Y. Acad. Sci. 1218, 3–14
72. Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clézardin, P., and
Peyruchaud, O. (2006) The type 1 lysophosphatidic acid receptor is a
target for therapy in bone metastases. Proc. Natl. Acad. Sci. U.S.A. 103,
9643–9648
73. Rogers,M. J. (2003)New insights into themolecularmechanisms of action
of bisphosphonates. Curr. Pharm. Des. 9, 2643–2658
74. Gidley, J., Openshaw, S., Pring, E. T., Sale, S., and Mansell, J. P. (2006)
Lysophosphatidic acid cooperates with 1,25(OH)2D3 in stimulating hu-
man MG63 osteoblast maturation. Prostaglandins Other Lipid Mediat.
80, 46–61
75. Miyabe, Y., Miyabe, C., Iwai, Y., Takayasu, A., Fukuda, S., Yokoyama, W.,
Nagai, J., Jona, M., Tokuhara, Y., Ohkawa, R., Albers, H. M., Ovaa, H.,
Aoki, J., Chun, J., Yatomi, Y., Ueda, H., Miyasaka, M., Miyasaka, N., and
Nanki, T. (2013) Necessity of lysophosphatidic acid receptor 1 for devel-
opment of arthritis. Arthritis Rheum. 65, 2037–2047
LPA1 in Osteoclast Activity
6564 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 10•MARCH 7, 2014
